Johnson & Johnson operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Johnson & Johnson with three other major healthcare and pharmaceutical companies: Bristol-Myers Squibb Company (2019 sales of $26.15 billion of which 30% was Prioritized Brands-Eliquis), Baxter International Inc. ($11.36 billion of which 54% was Americas), and Novartis AG which is based in SWITZERLAND (48.29 billion Swiss Francs [US$51.43 billion] of which 78% was Innovative Medicines).

Sales Analysis. During the year ended December of 2019, sales at Johnson & Johnson were $82.06 billion. This is a very small increase of 0.6% versus 2018, when the company's sales were $81.58 billion. This was the fourth straight year of sales growth at Johnson & Johnson. Sales of Pharmaceutical saw an increase that was more than double the company's growth rate: sales were up 3.6% in 2019, from $40.73 billion to $42.20 billion. Not all segments of Johnson & Johnson experienced an increase in sales in 2019: sales of Medical Devices fell 3.8% to $25.96 billion.